---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-113091"
form_type: "8-K"
ticker: "DMRA"
cik: "0001800315"
company_name: "Damora Therapeutics, Inc."
filed_at: "2024-10-07T23:59:59+00:00"
generated_at: "2026-05-30T19:24:59.651400+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Galecto acquires global rights to BRM-1420 dual ENL-YEATS/FLT3 inhibitor for AML

## Summary
- Galecto issued 62,594 common shares and 160.562 Series A convertible preferred shares (convertible into 160,562 common) to Bridge Medicines.
- BRM-1420 is a novel dual ENL-YEATS and FLT3 inhibitor targeting multiple genetic subsets of acute myeloid leukemia (AML).
- Carl Goldfischer, Galecto's Chairman, also serves as Executive Chairman of Bridge Medicines (related-party transaction).
- Pro forma impact: cash reduced by $2.68M; total consideration valued at stock issuance; assumes liabilities.
- Stockholder approval required for conversion of preferred shares; Bridge Medicines restricted from selling shares for 12 months.

## SEC filing metadata
- accession: 0000950170-24-113091
- form_type: 8-K
- ticker: DMRA
- cik: 0001800315
- company_name: Damora Therapeutics, Inc.
- filed_at: 2024-10-07T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 2.01, 3.02, 5.02, 5.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1800315/000095017024113091/0000950170-24-113091-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1800315/000095017024113091/glto-20241007.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-113091
- JSON: https://secwatch.observer/filing/0000950170-24-113091.json
- Plain text: https://secwatch.observer/filing/0000950170-24-113091.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.